Short-term results from the CamRelief phase 3 trial show that neoadjuvant camrelizumab (AiRuiKa) plus chemotherapy improves the rate of pathological complete response (pCR) when compared with chemotherapy alone in early or locally advanced triple-negative breast cancer (TNBC). The findings, (Abstract GS3-06) presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in…
An analysis of the chemotherapy cohort from the ADAPT trial found that nanoparticle albumin-bound (nab)-paclitaxel (PAC) had similar outcomes to solvent-based (sb)-PAC in patients with high-risk hormone receptor (HR)-positive, HER2-negative early breast cancer who were preselected by recurrence score and endocrine response. The findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) (Abstract…
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat…
